Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
Returns on capital
Accendra Health, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
238.8%
avg 11.9%
ROIC
8.4%
avg 3.1%
ROA
-44.9%
avg -4.5%
Analysis
ROE is currently the strongest return metric at 238.8% versus its period average of 11.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Edward A. Pesicka | President, Chief Executive Officer & Director | USD 1.6M | 58 | 1.07M | 1.40% |
Jonathan A. Leon | Executive Vice President, Chief Financial Officer & Corporate Treasurer | USD 889.41K | 59 | 286.27K | 0.37% |
Heath H. Galloway | Executive Vice President, General Counsel & Corporate Secretary | USD 797.22K | 49 | 166.31K | 0.22% |
Perry A. Bernocchi | Executive VP & COO | USD 774.4K | 67 | 313.91K | 0.41% |
Nicholas Piecora | Senior VP & Chief Information Officer | — | — | — | — |
Agnes Ansay | VP & Chief Procurement Officer | — | — | — | — |
Colin Bain | Chief Products Officer | — | — | — | — |
Trudi Allcott | Director of Media Relations | — | — | — | — |
Will Parrish | Vice President of Strategy of Corporate Development, & Investor Relations | — | — | — | — |
Dirk Benson | Chief Commercial Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Aug 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -34.8% | -2.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | +1.7% | +5.1% (5yr)2 analysts |
Analysis
Recent growth has been strongest in EBIT at +1.7% over three years. Forward estimates point to EBIT at +5.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Accendra Health, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ACH's management, answered from reported figures.
Who manages ACH?
Accendra Health, Inc. (ACH) lists 10 active executives. The top listed executive is Edward A. Pesicka, President, Chief Executive Officer & Director.
Are ACH insiders buying or selling?
Recent insider activity shows net buying of $14.82M.
Continue the stock analysis
Jump to another research area for this company.